News >

Headway Made in GI Cancer Treatment, But Progress Needed

Kristi Rosa
Published: Wednesday, Feb 27, 2019

Brandon Smaglo, MD, FACP

Brandon Smaglo, MD, FACP

With a new FDA approval in the third-line setting for patients with gastric cancer and research hinting at the opportunity for a personalized medicine approach, the space is bursting with new data to consider.

State of the Science Summit™ on Gastrointestinal Cancers, which took place just prior to the recent TAS-102 approval, Smaglo highlighted investigational treatment approaches for patients with gastric cancer and called for further research in the adjuvant setting to move the needle forward.

OncLive: Could you discuss the TAGS trial and the key findings?

Smaglo: TAGS was an interesting trial, largely because it was a study in the very late-line treatment of [patients with] gastric cancer—a third-line of treatment or higher. In many cancers, we do have multiple lines of therapy, but in gastric cancer, we've really been focused a lot on first-line therapy, with only a little bit [of a focus] on second-line treatment. So, to have a study that was focused on that late-line [of therapy] was very unique and it turned out to be very important for the management of our patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication